Summaries of health policy coverage from major news organizations
Bristol-Myers Squibb Applies for European Approval of Experimental HIV Drug Atazanavir
Bristol-Myers Squibb yesterday announced that it has submitted an application to the European Medicines Evaluation Agency for marketing approval of its new antiretroviral drug atazanavir, Reuters/New York Times reports (Reuters/New York Times, 5/30). The drug, currently in phase III clinical development, is a protease inhibitor that is taken once per day. The drug would compete with Merck's Crixivan and Pfizer's Viracept, two other protease inhibitors that are approved for use in Europe and the United States. Bristol-Myers said in April that it planned to seek U.S. marketing approval for atazanavir (previously known as BMS-232632) in the fourth quarter of this year (Reuters, 5/29).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.